Feng Ming-Xuan, Ma Ming-Ze, Fu Ying, Li Jun, Wang Tao, Xue Feng, Zhang Jian-Jun, Qin Wen-Xin, Gu Jian-Ren, Zhang Zhi-Gang, Xia Qiang
Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 160 Pujian Road, Shanghai, Shanghai 200127, China.
Mol Cancer. 2014 Oct 1;13:226. doi: 10.1186/1476-4598-13-226.
A remolded microenvironment in hepatocellular carcinoma (HCC) caused by abnormally expressed matricellular proteins could promote HCC progression. The cell-matrix interactions mediated by integrins play an important role in tumor microenvironment. Epidermal Growth Factor-like repeats and Discoidin I-Like Domains 3 (EDIL3), an extracellular matrix (ECM) protein with angiogenic and anti-inflammatory effects, is abnormally highly expressed in HCC. Here we aim to analyze its expression in liver and HCC tissues, investigate the underlined mechanisms accounted for HCC progression.
EDIL3 expression level is examined in normal liver, cirrhotic liver and HCC at both mRNA and protein level. The association between EDIL3 and clinical outcomes is analyzed. The pattern of EDIL3 expression and location is examined using Immunofluorescence and ELISA. Overexpression or knock-down of EDIL3 in a panel of cell lines are subjected to assays related to proliferation, invasion, and anoikis to investigate the mechanisms of this matrix protein in HCC progression. Recombinant EDIL3 treatment is applied to confirm the results.
Compared with normal liver and cirrhotic liver, EDIL3 is elevated in HCC. High level of EDIL3 protein is much more commonly in patients with larger tumor or portal vein tumor thrombus (PVTT) formation, associated with poor prognosis. EDIL3 is abundantly expressed in HCC cells and secreted by cancer cells. In vitro and in vivo studies indicate that EDIL3, probably in an autocrine manner, inhibits anoikis and promotes anchorage-independent growth of HCC cells. Further mechanistic studies suggest integrin ligation by EDIL3 and thus that the sustained activation of the FAK-Src-AKT signal is responsible for the anoikis resistance and anchorage independence. Both the administration of cilengitide, a RGD-containing integrin antagonist, and silencing of integrin αV, an important RGD-binding integrin, results in the blockade of anoikis-resistance induced by EDIL3.
Our study suggests that high levels of autocrine EDIL3 may contribute to a receptive microenvironment for the survival of detached HCC cells and may involve in cancer cell spreading. We also highlight the importance of interaction between EDIL3 and integrin αV and suggest disrupting the ligation of EDIL3 to integrins via RGD-blocking in selected patients may bear potential therapeutic value.
由异常表达的基质细胞蛋白重塑的肝细胞癌(HCC)微环境可促进肝癌进展。整合素介导的细胞与基质相互作用在肿瘤微环境中起重要作用。表皮生长因子样重复序列和盘状结构域蛋白3(EDIL3)是一种具有血管生成和抗炎作用的细胞外基质(ECM)蛋白,在肝癌中异常高表达。本研究旨在分析其在肝脏和肝癌组织中的表达,探讨其促进肝癌进展的潜在机制。
在mRNA和蛋白质水平检测正常肝脏、肝硬化肝脏和肝癌组织中EDIL3的表达水平。分析EDIL3与临床预后的相关性。采用免疫荧光和酶联免疫吸附测定(ELISA)检测EDIL3的表达模式和定位。在一组细胞系中过表达或敲低EDIL3,进行与增殖、侵袭和失巢凋亡相关的检测,以研究这种基质蛋白在肝癌进展中的作用机制。应用重组EDIL3处理以证实结果。
与正常肝脏和肝硬化肝脏相比,肝癌组织中EDIL3表达升高。高水平的EDIL3蛋白在肿瘤较大或有门静脉癌栓(PVTT)形成的患者中更为常见,与预后不良相关。EDIL3在肝癌细胞中大量表达并由癌细胞分泌。体外和体内研究表明,EDIL3可能以自分泌方式抑制失巢凋亡,促进肝癌细胞的非锚定依赖性生长。进一步的机制研究表明,EDIL3与整合素结合,从而持续激活FAK-Src-AKT信号,导致失巢凋亡抗性和非锚定依赖性。给予含RGD的整合素拮抗剂西仑吉肽以及沉默重要的RGD结合整合素αV,均可导致EDIL3诱导的失巢凋亡抗性被阻断。
我们的研究表明,高水平的自分泌EDIL3可能有助于为脱离的肝癌细胞提供一个适宜的生存微环境,并可能参与癌细胞的扩散。我们还强调了EDIL3与整合素αV相互作用的重要性,并建议在特定患者中通过RGD阻断破坏EDIL3与整合素的结合可能具有潜在的治疗价值。